
    
      In order to improve prognoses for MRD+ patients who have undergone at least 2 cycles
      chemotherapies, patients will receive CAR-T therapy before HSCT, once they achieve MRD-
      remissions, they will subsequently receive HSCT if there are no contraindications.
    
  